Literature DB >> 16343059

Liver allograft radiotherapy to treat rejection in children: efficacy in orthotopic liver transplantation and long-term safety.

Xavier Stephenne1, Mustapha Najimi, Magda Janssen, Raymond Reding, Jean de Ville de Goyet, Etienne M Sokal.   

Abstract

BACKGROUND: We studied, retrospectively, the efficacy to control rejection and long-term safety of liver allograft radiotherapy (RT) performed in 14 children. Long-term safety data were collected with the prospect of possible use of RT in liver cell transplantation (LCT).
METHODS: Immune suppression included cyclosporine, azathioprine and prednisone. In case of intractable rejection, low-dose allograft RT was administered daily for 3 days, and short-term efficacy was evaluated by liver enzyme assays and histology. The long-term outcome was compared with that of 122 patients undergone transplantation and who had similar treatment, but no RT.
RESULTS: Survival at 15 years was 71.4% vs 69.7% in the comparison group. In the RT group, rejection control was complete in six of 14 children and partial in two, all being alive and well 14-18 years later. Ten of 14 children had follow-up biopsy. Six children had normal histology and four had mild unspecific fibrosis. The long-term follow-up biopsy in the comparison group showed fibrosis in 42 of 85 children. The incidence of complications was similar in both groups.
CONCLUSIONS: This series shows that, such a RT regimen appeared to be efficient and safe as a rescue treatment for acute rejection. Provided that further investigations in animal models show a certain benefit of low-dose irradiation around LCT, such a regimen could be proposed in human liver cell transplant programmes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343059     DOI: 10.1111/j.1478-3231.2005.01152.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  1 in total

1.  Hepatocyte Transplantation in Special Populations: Clinical Use in Children.

Authors:  Zahida Khan; Stephen C Strom
Journal:  Methods Mol Biol       Date:  2017
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.